{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T21:40:21Z","timestamp":1738186821153,"version":"3.34.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.msard.2024.106249","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T16:12:08Z","timestamp":1735143128000},"page":"106249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MOG IgG antibody positivity from laboratory to clinical practice: A real world experience"],"prefix":"10.1016","volume":"93","author":[{"given":"Tejas","family":"Shivarthi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahima","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muddana","family":"Nikhilesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pula","family":"Rohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Sudeep Reddy","family":"Jinna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-2774","authenticated-orcid":false,"given":"Sudheeran","family":"Kannoth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udit","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siby","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopikrishnan","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anandkumar","family":"Anandakuttan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamma","family":"Mathai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meena","family":"Thevarkalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suprabha","family":"Panicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishakh","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K P","family":"Vinayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abish","family":"Sudhakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.106249_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105150","article-title":"Utility of the 2023 international MOGAD panel proposed criteria in clinical practice: an institutional cohort","volume":"81","author":"Alaboudi","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.106249_bib0001","first-page":"1","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management","volume":"22","author":"Ambrosius","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2024.106249_bib0010","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106249_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105950","article-title":"Clinical characteristics of pediatric and adult myelin oligodendrocyte antibody-associated disease (MOGAD): a single-center study in the Northeast","volume":"92","author":"Brown","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2024.106249_bib0025","first-page":"A16","article-title":"MOGAD headache or migraine: when, what and how to recognise?","volume":"95","author":"Chance","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2024.106249_bib0004","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","article-title":"MOG antibody-related disorders: common features and uncommon presentations","volume":"264","author":"Cobo-Calvo","year":"2017","journal-title":"J. Neurol."},{"issue":"21","key":"10.1016\/j.msard.2024.106249_bib0032","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2024.106249_bib0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2024.106249_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12111529","article-title":"MOGAD involving cranial neuropathies: a case report and review of literature","volume":"12","author":"Du","year":"2022","journal-title":"Brain Sci."},{"issue":"9","key":"10.1016\/j.msard.2024.106249_bib0030","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.msard.2024.106249_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103229","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: the difficulty of predicting relapses","volume":"56","author":"Epstein","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106249_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-333227","article-title":"Validation of the international MOGAD panel proposed criteria: a single-centre US study","author":"Filippatou","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2024.106249_bib0041","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209682","article-title":"Investigating the 2023 MOGAD criteria in children and adults with MOG-antibody positivity within and outside attacks","volume":"103","author":"Fonseca","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2024.106249_bib0012","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200183","article-title":"Timing of MOG-IgG testing is key to 2023 MOGAD diagnostic criteria","volume":"11","author":"Forcadela","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2024.106249_bib0011","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/13524585231172960","article-title":"Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: commentary","volume":"29","author":"Gastaldi","year":"2023","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.msard.2024.106249_bib0031","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.msard.2024.106249_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.msard.2024.106249_bib0026","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation."},{"issue":"12","key":"10.1016\/j.msard.2024.106249_bib0006","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.106249_bib0021","series-title":"Indian Journal of Pediatrics (Vol. 90, Issue 2, p. 200)","article-title":"MRI-negative MOG antibody-associated disease in meningitis","author":"Kesavan","year":"2023"},{"issue":"12","key":"10.1016\/j.msard.2024.106249_bib0029","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106249_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.spen.2023.101056","article-title":"Myelin oligodendrocyte glycoprotein (MOG) associated diseases: updates in pediatric practice","volume":"46","author":"Khoshnood","year":"2023","journal-title":"Semin. Pediatr. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.106249_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.106249_bib0024","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/6724448","article-title":"Sensorineural hearing loss in seropositive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disorder","author":"Kwon","year":"2024","journal-title":"Acta Neurol. Scand."},{"issue":"11","key":"10.1016\/j.msard.2024.106249_bib0035","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.106249_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104736","article-title":"The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia","volume":"75","author":"Lalwani","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2024.106249_bib0017","first-page":"1865","article-title":"Diagnostic value of low versus high titers of MOG-IgG and their clinical implications in myelin oligodendrocyte glycoprotein antibody-associated disease: a retrospective single-center study","volume":"43","author":"Li","year":"2023","journal-title":"Nan. Fang. Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.msard.2024.106249_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104126","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated aseptic meningitis without neurological parenchymal lesions: a novel phenotype: Imaging-negative MOGAM clinical features","volume":"68","author":"Lin","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106249_bib0009","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106249_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105497","article-title":"Clinical analysis of myelin oligodendrocyte glycoprotein antibody-associated disease in a diverse cohort of children: a single-center observational study","volume":"84","author":"Nguyen","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106249_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1252650","article-title":"Comparison of live and fixed cell-based assay performance: implications for the diagnosis of MOGAD in a low-middle income country","volume":"14","author":"Pandit","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2024.106249_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.867190","article-title":"Volumetric brain loss correlates with a relapsing MOGAD disease course","volume":"13","author":"Rechtman","year":"2022","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2024.106249_bib0013","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.106249_bib0014","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2024.106249_bib0016","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/13524585231172954","article-title":"Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes","volume":"29","author":"Reindl","year":"2023","journal-title":"Mult. Scler"},{"issue":"1","key":"10.1016\/j.msard.2024.106249_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody\u2013associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.msard.2024.106249_bib0002","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.106249_bib0037","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1352458520907900","article-title":"Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies","volume":"27","author":"Sechi","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106249_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1192644","article-title":"High level of agreement in a fixed vs. live cell-based assay for antibodies to myelin oligodendrocyte glycoprotein in a real-world clinical laboratory setting","volume":"14","author":"Smith","year":"2023","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.106249_bib0003","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.106249_bib0023","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1352458519840747","article-title":"Relapsing lumbosacral myeloradiculitis: an unusual presentation of MOG antibody disease","volume":"26","author":"Sundaram","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2024.106249_bib0034","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2024.106249_bib0038","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T21:00:24Z","timestamp":1738184424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824008253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":43,"alternative-id":["S2211034824008253"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106249","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MOG IgG antibody positivity from laboratory to clinical practice: A real world experience","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106249"}}